Artiva Biotherapeutics (NASDAQ:ARTV) Rating Lowered to Neutral at Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV) was downgraded by Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat reports. They presently have a $4.00 price objective on the stock. Wedbush‘s price objective suggests a potential downside of 5.97% from the stock’s previous close.

Several other analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Monday, October 19th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Artiva Biotherapeutics presently has an average rating of “Hold” and an average price target of $30.00.

Artiva Biotherapeutics Trading Down 30.9%

Artiva Biotherapeutics stock traded down $1.91 during trading hours on Tuesday, hitting $4.25. 6,503,364 shares of the stock traded hands, compared to its average volume of 425,159. The firm’s 50-day moving average price is $8.80 and its two-hundred day moving average price is $7.96. The company has a market cap of $207.98 million, a PE ratio of -1.29 and a beta of 2.40. Artiva Biotherapeutics has a one year low of $2.96 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). On average, sell-side analysts expect that Artiva Biotherapeutics will post -2.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Jennifer Bush sold 8,370 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the sale, the chief operating officer owned 366,159 shares in the company, valued at $2,504,527.56. This represents a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Subhashis Banerjee sold 8,222 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total value of $98,746.22. Following the completion of the sale, the insider owned 142,047 shares in the company, valued at $1,705,984.47. The trade was a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 137,048 shares of company stock worth $1,086,167 over the last three months. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. 5AM Venture Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $22,827,049. Blue Owl Capital Holdings LP bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $8,483,000. BlackRock Inc. bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $6,739,000. Nantahala Capital Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter valued at approximately $2,910,000. Finally, Alyeska Investment Group L.P. lifted its position in Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after acquiring an additional 173,615 shares in the last quarter.

Artiva Biotherapeutics News Roundup

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported approximately $319.1 million in cash, cash equivalents and investments as of September 30, 2026, providing financial resources while it evaluates strategic alternatives. Leerink Partners has been hired as financial adviser. Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
• Neutral Sentiment: Trading in ARTV was temporarily halted for news before the strategic update was released, increasing volatility and limiting trading during the announcement.
• Negative Sentiment: The company cited two recent Grade 5 safety events, including a case of leukoencephalopathy assessed as likely related to fludarabine toxicity and another event assessed as unrelated to the study treatment. Reports describe the events as two patient deaths. Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%
• Negative Sentiment: Although updated data continued to show B-cell depletion and clinical responses, longer-term follow-up indicated that response durability did not meet Artiva’s threshold for continued development. Ending the lead program removes the company’s primary clinical catalyst and commercial opportunity.
• Negative Sentiment: Artiva plans to reduce its workforce by approximately 94% as it explores strategic options, signaling a major contraction of operations and uncertainty about the company’s future as an independent developer. Artiva Biotherapeutics stock tumbles after halting drug trial
• Negative Sentiment: Analysts reacted negatively: Needham cut its rating from Buy to Hold, while Wedbush downgraded the stock from Outperform to Neutral and set a $4.00 price target. Artiva Biotherapeutics Ends AlloNK Program, Explores Strategic Options

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.